Recital 4, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

In forcesince 16 Dec 1999cited 3×

orphan medicinal products eligible for incentives should be easily and unequivocally identified; it seems most appropriate to achieve this result through the establishment of an open and transparent Community procedure for the designation of potential medicinal products as orphan medicinal products;

  • Judgment of the General Court (Seventh Chamber) of 16 May 2019 (Extracts). GMP-Orphan (GMPO) v European Commission.Decision

    16 May 2019 · 62017TJ0733

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision

    Fourthly, it is apparent from recitals 1, 2 and 4 in the preamble to Regulation No 141/2000 that the intention of the legislature was to provide for measures to stimulate the research and development of potential orphan medicinal products …

    9 Sep 2010 · 62007TJ0264

  • Judgment of the Court (Eighth Chamber) of 29 July 2019. European Medicines Agency v Shire Pharmaceuticals Ireland Ltd.Decision

    That interpretation is supported by recital 4 of Regulation No 141/2000 which states that ‘orphan products eligible for incentives should be easily and unequivocally identified’. The purpose of the term ‘eligible for’ is to …

    29 Jul 2019 · 62018CJ0359